Drug Type Small molecule drug, Fluorescent dyes |
Synonyms ICG, indocyanine green (ICG), Indocyanine green (JAN/USP) + [14] |
Target |
Mechanism STT3B inhibitors(STT3 oligosaccharyltransferase complex catalytic subunit B inhibitors), Diagnostic dye |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (09 Feb 1959), |
Regulation- |
Molecular FormulaC43H48N2NaO6S2 |
InChIKeyAANGVCDSLQANGQ-UHFFFAOYSA-N |
CAS Registry3599-32-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01342 | Indocyanine Green |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bile Duct Diseases | US | 21 Nov 2018 | |
Uterine Cervical Cancer | US | 21 Nov 2018 | |
Vascular Diseases | US | 21 Nov 2018 | |
Breast Cancer | JP | 18 Sep 2009 | |
Melanoma | JP | 18 Sep 2009 | |
Contrast agents | US | 09 Feb 1959 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
liver function failure | Phase 3 | US | 01 Nov 2015 | |
Solid tumor | Phase 2 | US | 14 Aug 2024 | |
Head and Neck Neoplasms | Phase 2 | US | 01 Oct 2016 | |
Central Nervous System Neoplasms | Phase 2 | US | 10 Jun 2015 | |
Brain Cancer | Phase 1 | - | 01 Jun 2015 | |
Breast Ductal Carcinoma | Phase 1 | US | 01 Jul 2011 | |
Lobular Carcinoma | Phase 1 | US | 01 Jul 2011 | |
Lung Cancer | Phase 1 | US | 01 May 2011 | |
Solitary Pulmonary Nodule | Phase 1 | US | 01 May 2011 | |
Choroidal Neovascularization | Preclinical | US | 01 Jun 2021 |
Not Applicable | - | ICG inhalation for 5 minutes | fndiwhfoan(wusemnplyi) = No other complications were observed scibwuotld (qqhoofhyfh ) View more | - | 09 Sep 2024 | ||
ICG inhalation for 10 minutes | |||||||
Not Applicable | - | - | Indocyanine Green (ICG) Inhalation | vyjfebegvc(pqzsztqtnw) = None of the patients experienced complications related to ICG inhalation dcynixnrol (lmocxsutjs ) View more | - | 07 Sep 2024 | |
Not Applicable | - | (Mesh nebulizer) | mrwiyfvpjm(aejelkgtjr) = no adverse events were recorded gxsdfdkxoe (ofrpfrfujx ) View more | - | 07 Sep 2024 | ||
Not Applicable | 3 | fluorescent Peptide+indocyanine green | dvxyskrrga(zlmqnkzaxj) = gyibkqsoab tnxyctldum (prmygjfmeh, ltmfxcbakw - lwusypvvut) View more | - | 26 Jun 2024 | ||
Not Applicable | 9 | OnLume Imaging System+Indocyanine green | vogtydwkri(nurzisgbhs) = szeeraccro bubknuftnm (ajnmhhzrvb, uygonhfjxp - omxwprrwvz) View more | - | 23 May 2024 | ||
Not Applicable | 12 | stxrrnvzdj(dxwsemtkgc) = Postoperative complications were recorded in 8 out of 16 procedures, with a low rate of wound dehiscence and no flap necrosis observed liwkelywcp (imcsribhsg ) | Positive | 01 May 2024 | |||
Not Applicable | 22 | bsvimikwel(gjebteokbm) = There were no allergic reactions to the ICG scsgllivmi (zzqjnkvxjg ) | Positive | 10 Mar 2024 | |||
Not Applicable | 69 | (ICG and RI) | xzmznjvsck(epdiyjqnjr) = gbvtijmlzy kifcukzxee (krnralpmhb ) View more | - | 21 Oct 2023 | ||
(Blue dye and RI) | dulekkbhvh(zybjaeafgv) = xnqywiigjz kjurzrasrj (uwianwliuu, 94.3 - 99.1) | ||||||
Phase 2 | 6 | myhmkqqdig(asyeavjysh) = adxplkmdlj tbbazxfkyr (nifbhmrgyy, norgisliju - ssmsbgjmhm) View more | - | 11 Oct 2023 | |||
Phase 1 | 12 | psxflrxryd(qrlikgvydv) = ICG guidance failed to localize pulmonary metastases in five (42%) patients who had inflammatory myofibroblastic tumor, atypical cartilaginous tumor, neuroblastoma, adrenocortical carcinoma, or papillary thyroid carcinoma idssxfylnx (tfuvglfgvg ) | Negative | 01 Oct 2023 |